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Impairment in episodic memory is typically the earliest clinical deficit to appear in 
Alzheimer's disease (AD), the most common cause of dementia and a source of immense 
personal and societal burden. Unfortunately, the mechanisms underlying AD and other age-
related conditions causing cognitive deficits are only partially understood, limiting the 
development of disease-modifying therapies and novel early diagnostic biomarkers.
Recently, we reported the discovery of a SNP in the FASTKD2 gene associated with better 
memory performance in a large sample of older Americans [1]. We also demonstrated that 
this new memory-protective SNP was associated with increased volume and gray matter 
density in the hippocampus, a key brain structure for encoding and retrieving memories that 
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is among the earliest regions affected by AD. Shortly thereafter, a separate report from an 
independent group identified perturbations in FASTKD2 expression in brain astrocytes 
derived from postmortem tissue samples from AD patients [2].
Prior to these studies, FASTKD2 had not been linked to cognition or AD. This new evidence 
obtained through diverse methodologies and analytical strategies suggests that FASTKD2 
may have potential as a novel target for biomarker and drug development against AD and 
age-associated cognitive decline. As a result, this is an opportune moment to critically 
appraise extant knowledge about FASTKD2 and its functional pathways in order to guide 
next steps aimed at translating mechanistic knowledge into potential clinical strategies.
FASTKD protein family
FASTKD2 encodes one of a family of proteins (including FASTK and FASTKD1–5) that 
share a common structure including a mitochondrial targeting domain, multiple serine/
threonine kinase domains and an RNA-binding domain [3]. Much of the early literature on 
this protein family focuses on FASTK, which constitutively inhibits apoptosis when tethered 
to the outer mitochondrial membrane but promotes apoptosis when released to the cell 
cytoplasm following activation of the Fas/CD95 ‘death receptor’ [3,4]. The proapoptotic 
function of FASTK is mediated by its binding and modulating the function of TIA1, an 
mRNA-binding protein that normally silences the production of apoptotic and inflammatory 
mediators including TNF-α [5].
As discussed below, initial studies of the other FASTKD protein family members indicate 
broadly shared functions with FASTK. This evidence is not surprising given the common 
structure and mitochondrial localization of these proteins. However, a closer examination of 
these putative functional pathways can provide mechanistic clues to characterize the 
particular impact of FASTKD2 on brain structure and function (Supplementary Figure 1; see 
online at: www.future-medicine.com/doi/suppl/10.2217/pgs.15.8).
FASTKD2 & apoptosis
The first functional study of FASTKD2 ensued following the discovery of gene mutations 
causing a rare mitochondrial encephalomyopathy [6]. Due to its FASTK domain, the authors 
hypothesized a role for the FASTKD2 protein in apoptosis and found that on treatment with 
staurosporine (a well-described inducer of apoptosis), cells with loss-of-function FASTKD2 
mutations exhibited less apoptosis while cells with FASTKD2 overexpression exhibited 
more apoptosis [6].
Subsequent studies identified FASTKD2 as a vital part – along with NRIF3 and DIF1 – of a 
‘death switch’ modulating apoptosis in cancer cells [7,8]. Further insight can also be found 
in the broader interaction network for the FASTKD2 protein, which includes numerous 
proapoptotic factors including TRAF6, TSC22D1 and c-Myc [9].
In our report, we demonstrated that the novel FASTKD2 SNP associated with better memory 
performance was also associated with lower levels in cerebrospinal fluid of four proteins 
involved in fas-mediated apoptosis [1]. Although it was beyond the scope of our manuscript 
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to directly assess the impact of this SNP on activation of apoptosis at the cellular level, this 
additional finding suggests that modulation of cell death pathways may account for the 
neuroprotective effect of FASTKD2 on memory.
FASTKD2 & mitochondrial function
The protein encoded by FASTKD2 localizes to the inner mitochondrial membrane and is 
expressed at its highest levels in the richly energy-dependent tissues of the brain [6,10]. A 
nonsense mutation in FASTKD2 is known to underlie respiratory chain complex IV 
(cytochrome c oxidase) deficiency, a rare and typically fatal disorder that presents in infancy 
with developmental delay, myopathy and encephalopathy including demyelinating brain 
lesions and epilepsy [6,11]. Recently, missense FASTKD2 mutations were also identified in 
patients with inherited ataxias, a heterogeneous group of disorders with frequent 
mitochondrial origin [12].
It is not yet known how these FASTKD2 mutations lead to their cellular and clinical 
phenotypes. For example, while FASTKD2 may be directly involved in the synthesis, 
localization and/or function of cytochrome c oxidase, it is also possible that knocking out 
FASTKD2 starts a chain of events yielding broader mitochondrial dysfunction negatively 
impacting the respiratory chain and its central role in cellular energetics. Indeed, the protein 
encoded by family member FASTKD3 is known to interact with both respiratory chain 
components and mitochondrial DNA translation machinery [3], suggesting broad potential 
functionality of this protein class in the cellular powerhouse. Further study will be needed to 
better understand the pathogenic sequence initiated by rare mutations as well as more 
common genetic variants.
Beyond these findings in rare genetic conditions, mitochondrial dysfunction and closely 
related oxidative stress pathways are major candidate mechanisms proposed to underlie 
neurodegeneration in aging and disease [13,14]. The new identification of expression 
changes in FASTKD2 and other mitochondrial genes in AD brain cells burnishes this 
hypothesis and enhances the foundation for additional functional genomics studies to clarify 
underlying mechanisms [2].
FASTKD2 & inflammation
Despite the mitochondrial localization of its encoded protein, there is an increasing body of 
work suggesting a proinflammatory role for FASTKD2. A likely mechanism for this effect 
may be related to the FASTK domain and its inhibition of TIA1, ultimately promoting 
production of the systemic inflammation mediator TNF-α [15,16]. The Fas/FasL axis is 
itself considered a strong regulator of inflammation and in some biological contexts may 
lead to tissue damage through inflammatory responses rather than through apoptosis [17]. 
This evidence may be particularly compelling in the setting of AD, where inflammation and 
immune system activation are increasingly viewed as playing central roles in mediating 
and/or compensating for cellular stress induced by amyloid-β deposition [18,19].
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Population genomics analyses of additional data sets, including other relevant AD 
endophenotypes, may provide further insight regarding the clinical impact of FASTKD2. 
Expression studies using microarray or RNA-seq data will also be useful to examine the 
relationship between specific genetic variants and canonical transcripts as well as splice 
variant and other alternative transcripts. Finally, deep sequencing of the FASTKD2 locus in 
large samples will facilitate characterization of regional linkage disequilibrium structure 
(including functional ‘tag’ SNPs), other types of variants (including rare, copy number and 
structural variants) and epigenetic modification sites.
Functional genomic studies will also be crucial to elucidate the basic mechanisms 
connecting these genetic variants to expression and biological action. The overlap of two 
microRNA genes (MIR 3130-1 and 2) with the intron containing the memory-associated 
SNP raises the possibility that variants in this region may regulate microRNA-mediated 
silencing of gene expression [1]. However, other leading possibilities for further exploration 
include potential dysfunction in the FASTKD2 RNA-binding domain [20] or at transcription 
factor or splicing machinery-binding sites. Although FASTKD2 appears to lack homologs in 
yeast, worms and flies [6], the creation of mammalian models and/or cell lines will be vital 
for this effort and could be crossed with analogous AD model systems to directly assess the 
impact of knockout, knockdown and overexpression of FASTKD2.
Conclusion
Along with related new discoveries and prior functional studies of this gene, the novel 
association of FASTKD2 with memory performance and hippocampal structure potentially 
opens new avenues for exploration of strategies to modulate neurodegeneration in AD and 
cognitive aging. Given that genes and proteins do not act in isolation [21], a better 
understanding of the range of biological activities for FASTKD2 will help focus efforts to 
develop potential disease-modifying drugs targeting these functional pathways.
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